EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma
Takeda Pharmaceutical Company Limited announced that the EC extended the current marketing authorization of ADCETRIS (brentuximab vedotin) to include treatment...